Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

The data will be presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting, which takes place March 7-11, 2025, highlighting HT-001 as a potential breakthrough therapy for EGFR inhibitor-induced dermatologic toxicities. The recent case study will be highlighted that…